| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10163329 | Pediatria Polska | 2014 | 9 Pages |
Abstract
Since the introduction of rotavirus vaccine, diarrhea-associated Emergency Department (ED) visits and hospitalizations of children have decreased substantially in countries with Universal Mass Vaccination (UMV). Currently two live, oral, attenuated rotavirus vaccines are available: the monovalent (RV1) Rotarix® (GlaxoSmithKline Biologicals, Rixensart, Belgium) and the pentavalent (RV5) RotaTeq® (Merck & Co. Inc., West Point, PA, USA). In April 2009, the World Health Organization's Strategic Advisory Group of Experts on immunization (SAGE) recommended the introduction of RV vaccines in all national immunization programs. This paper presenting result of a systematic review of the literature, focusing on efficacy, effectiveness, impact and safety of RV vaccines, and on the local epidemiology of RV infections as well is the scientific background for recommendation of RV vaccines for polish infants in National Program of Immunization.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Teresa Jackowska, Dominika Kowalska-Kuassi, Elżbieta OÅdak, Jacek Wysocki,